08:35 AM EDT, 07/14/2025 (MT Newswires) -- Dare Bioscience ( DARE ) said Monday that interim results from its phase 3 clinical trial showed that its investigational monthly, hormone-free intravaginal contraceptive, Ovaprene, met the company's expectations.

The company said about 9% of women treated in the trial had experienced a pregnancy during the interim analysis, consistent with what Dare Bioscience ( DARE ) had expected based on the postcoital test clinical study results.

Dare Bioscience ( DARE ) reported no new safety or tolerability concerns.

The company added that about 17% of participants discontinued the study because of the most commonly reported product-linked adverse event, which is vaginal odor.

Dare Bioscience ( DARE ) shares surged 230% in recent premarket activity.